SCHEMBL5705173

SCHEMBL5705173

CC(C)(C)OC(=O)N1CCC(c2cn(Cc3ccc(C(C)(C)C)cc3)c3cc(O)ccc23)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 2/20 0.46
SLC5A1 P13866 1/20 0.42
SLC5A2 P31639 1/20 0.42
TGFBR1 P36897 2/20 0.41
TP53 P04637 1/20 0.40
ALDH1A1 P00352 1/20 0.40
LMNA P02545 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
GPR119 Q8TDV5 1/20 0.40
KDM4E B2RXH2 2/20 0.39
MAPT P10636 1/20 0.39
THRB P10828 1/20 0.39
KDM1A O60341 1/20 0.39
VEGFA P15692 1/20 0.39
EGLN1 Q9GZT9 1/20 0.39
PARP1 P09874 2/20 0.39
PARP2 Q9UGN5 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6133175 0.90 SCN9A (0.46) SCN9ASLC5A1SLC5A2TGFBR1TP53
SCHEMBL5705137 0.90 GPR119 (0.47) SCN9ASLC5A1SLC5A2TGFBR1ALDH1A1
SCHEMBL6133259 0.87 YAP1 (0.48) SCN9ASLC5A1SLC5A2ALDH1A1LMNA
SCHEMBL5705142 0.84 ALDH1A1 (0.47) SCN9ASLC5A1SLC5A2TGFBR1TP53
SCHEMBL6135457 0.84 JAK2 (0.42) SCN9ASLC5A1SLC5A2TGFBR1TP53
SCHEMBL6133467 0.76 GPR119 (0.54) SCN9AGPR119
SCHEMBL5705160 0.76 SLC2A1 (0.52) SCN9ASLC5A1SLC5A2ALDH1A1LMNA
SCHEMBL17398495 0.72 ESR2 (0.52) TP53ALDH1A1GPR119KDM4EMAPT
SCHEMBL1979040 0.72 KDM4E (0.53) SCN9ATGFBR1ALDH1A1GPR119KDM4E
SCHEMBL17398401 0.72 KDM4E (0.53) TGFBR1ALDH1A1GPR119KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1691807-A1 INDOLE DERIVATIVES FOR THE TREATMENT OF BONE DISEASES Astellas Pharma Inc. (JP) 2006-08-23 EP disclosed
US-20050245540-A1 New methods FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-11-03 US disclosed
WO-2005056012-A1 INDOLE DERIVATIVES FOR THE TREATMENT OF BONE DISEASES ASTELLAS PHARMA INC. (JP) 2005-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050245540-A1 New methods TGFB1, TGFBR1, TGFB2 SCN9A 2148/4885SLC5A1 368/4885SLC5A2 691/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.